SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-23-021960
Filing Date
2023-05-15
Accepted
2023-05-15 07:08:37
Documents
73
Period of Report
2023-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q fulc-20230331.htm   iXBRL 10-Q 2584509
2 EX-10.1 fulc-ex10_1.htm EX-10.1 59990
3 EX-31.1 fulc-ex31_1.htm EX-31.1 15994
4 EX-32.1 fulc-ex32_1.htm EX-32.1 8953
  Complete submission text file 0000950170-23-021960.txt   9252902

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT fulc-20230331_pre.xml EX-101.PRE 380087
6 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT fulc-20230331_def.xml EX-101.DEF 247423
7 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT fulc-20230331.xsd EX-101.SCH 62175
8 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT fulc-20230331_cal.xml EX-101.CAL 45634
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT fulc-20230331_lab.xml EX-101.LAB 475075
67 EXTRACTED XBRL INSTANCE DOCUMENT fulc-20230331_htm.xml XML 1733250
Mailing Address 26 LANDSDOWNE STREET CAMBRIDGE MA 02139
Business Address 26 LANDSDOWNE STREET CAMBRIDGE MA 02139 617-651-8851
Fulcrum Therapeutics, Inc. (Filer) CIK: 0001680581 (see all company filings)

IRS No.: 474839948 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38978 | Film No.: 23918353
SIC: 2834 Pharmaceutical Preparations